One clock

A company's strategy, sales cycle, budget, funding cycle and cap table are not five things that need managing. They are one mechanism, and it has a single rate. Most expensive failures I have watched were not failures of judgment at all — they were working parts running at different speeds, which is an arithmetic problem, and therefore one you can see coming.

The most useful sentence I know about running a company is not about vision or talent or focus. It is this: the strategy has to match the sales cycle, which has to match the budget, which has to match the funding cycle. Break the chain at any link and the other three cannot compensate for it.

It sounds like a truism. It is not treated as one. In practice these four are owned by different people, reviewed on different cadences, and discussed in different meetings — the strategy annually with the board, the pipeline weekly with the commercial team, the budget quarterly with finance, and the funding whenever the runway starts to look short. Four conversations about one machine, held separately, is how a company arrives at a plan in which every individual part is defensible and the whole is not.

The arithmetic, in its plainest form

Take a business selling something consequential to large organisations. The sales cycle — from first contact to signature to revenue — is eighteen months. That number is not a performance issue; it is a property of the buyer. They have a budget process, a risk function, a procurement department, and a set of internal stakeholders who each need to be brought along. Effort does not compress it much. Talent compresses it a little. Mostly it is what it is.

Now suppose the funding cycle is twelve months. Not unusual, and not unreasonable on its own terms.

Those two numbers describe a company that is structurally short of time. At the moment the next raise has to be justified, the work done since the last one has not yet had the chance to become evidence. The pipeline is real, the conversations are real, the progress is real — and none of it has landed in the form the next investor needs to see. Nothing has gone wrong. The clocks simply do not agree.

No amount of effort inside the period closes a gap that was set when the plan was written.

This is why I say the failure is arithmetic rather than character. It is entirely possible for everyone in such a company to be working well, selling well and building well, and for the outcome to be determined anyway. The determination happened earlier, in a planning conversation, when two numbers were set without being put next to each other.

Where the chain usually breaks

Four failure points, in the order I most often see them.

Strategy against sales cycle. A strategy that targets buyers whose purchasing rhythm is slower than the company's ability to wait. This is the most common one, and the most seductive, because the target customers are usually the right customers — the logos everyone wants, the contracts with real size. The strategy is correct in every respect except time.

Sales cycle against budget. A budget built on the assumption that the current quarter's activity produces this year's revenue, when the activity is in fact producing revenue eighteen months out. The result is a company that appears to miss continuously while doing exactly what it should be doing. Morale takes the damage that the plan earned.

Budget against funding cycle. A cost base sized to the ambition rather than to the runway. The classic form is hiring into a plan rather than into demonstrated demand — and the most dangerous moment for it is the week after a raise, when the bank balance argues loudly for confidence and the sales cycle has not yet had time to argue back.

Funding cycle against strategy. Capital whose expectations are shaped by a different kind of business entirely. This is the one that is least discussed and most consequential, and it deserves its own section.

Investors are not interchangeable

Capital is treated as fungible far more often than it is. A term sheet gets compared to another term sheet on price, dilution and control, and rather less on whether the investor understands the rate at which the business can actually move.

An investor who has spent their career with businesses that show traction in two quarters will, quite sincerely and with the best intentions, apply that expectation to a business whose proof arrives in eight. They will ask for evidence on a cadence the business cannot produce it, conclude that something is wrong, and press for changes — more sellers, faster cycles, smaller deals — that make the underlying problem worse. Nobody is behaving badly. The clock in the room is simply not the clock in the market.

An investor who does understand the rhythm is worth more than one offering a better price, and it is not close. They also know what sits on the other side of a long, risk-based cycle: a product that is extremely hard to displace, high gross margins, renewal that is close to automatic because switching is unthinkable, and a great deal of area under the curve. Patience is not indulgence in that structure. It is how the return is earned.

Which means matching the investor to the deal motion is part of designing the company. It belongs in the same conversation as the go-to-market and the hiring plan, not in a separate exercise called fundraising that happens when money is needed.

How big is big enough

The clock also answers a question that is usually treated as a negotiation: how much should the company raise?

It is not a matter of appetite, or of what the market will bear, or of what feels unembarrassing to ask for. The floor is set by the arithmetic already described. The raise has to buy enough runway to clear the next sales cycle, plus an error margin, plus the time it takes to convert a signature into the kind of evidence a next investor will actually credit. Anything below that line does not buy a smaller version of the outcome. It buys the same outcome as raising nothing, several months later, with the cap table already spent.

Which brings me to the most useful thing anyone told me about capital. I worked for a managing director early in my career who had run equity capital markets through a crisis in Asia, and who had two sayings. The first was this: rights issues should have an inverted demand curve until they are big enough to actually solve the problem.

The logic is exact. A recapitalisation that does not fix the balance sheet leaves you a shareholder in the same distressed company, only diluted. One that does fix it leaves you a shareholder in a solvent one. So appetite ought to increase with size — the opposite of how demand normally behaves — right up to the threshold where the problem is genuinely solved. Above that line, ordinary economics resume and additional capital is simply dilution without purpose. The curve is not inverted everywhere. It is inverted in the region that matters.

The value of capital to a long-cycle business is a step function. Almost everyone prices it linearly.

The instrument was a rights issue, but the shape transfers to any financing where the money is meant to reach a specific milestone. And the transfer is where it gets uncomfortable, because what I have most often seen in private markets is precisely the opposite instinct: an investor who likes the company and therefore proposes to put in less, in order to see proof first.

That instinct is not stupid. Under portfolio mathematics it is entirely rational — you are buying an option to double down later, at a price that will look cheap if things work and which you can walk away from if they do not. Reserves exist for exactly this. The difficulty is specific to businesses with long clocks: if the money provided cannot buy enough time for the proof to arrive, then the option has been bought and simultaneously guaranteed to expire out of the money. The investor has paid for information the structure prevents them from receiving.

The rational version of the same caution is available and costs nothing: I like this, and I will fund it only if the total round clears the bar. That preserves the discipline — the investor is not committing to an underfunded plan — while removing the part that is self-defeating. It is a better instrument for the same instinct.

The dilution path has to underwrite the strategy too

There is almost always a smaller raise available. That is what makes this hard: the alternative is not nothing, it is a different trajectory. Sometimes the smaller number is the right answer — a narrower plan, a slower build, a more concentrated bet — and if the plan is genuinely rewritten to match, the clocks can be brought back into agreement at the lower number. That is a legitimate choice, and occasionally the wise one.

What is not legitimate is taking the smaller number while keeping the larger plan. Then you have simply moved the mismatch somewhere it will not be discussed until it is expensive.

And there is a further constraint that tends to arrive late in these conversations, which is the dilution path itself. A round that is too small to reach the next proof point is followed by another round at a valuation that has not moved much — because the proof, by construction, did not arrive. The dilution per unit of actual progress is therefore worse, and it compounds. Two or three iterations of that and the ownership arithmetic no longer supports the strategy: the people who have to execute a decade-long plan no longer own enough of it for the plan to make sense to them, and the early investors are diluted below the position their own funds needed them to hold.

So the cap table is a fifth part of the mechanism, on the same clock as the other four. A funding strategy that produces a workable business and an unworkable ownership structure has not solved the problem; it has relocated it.

Who is doing what to whom, and why

The second saying from the same source was harder and more general: understand who is doing what to whom, and why, and you can navigate any situation. It sounds like cynicism. It is the opposite — it is the assumption that everyone in the room is behaving rationally given constraints you cannot see, and that your job is to find the constraints rather than to attribute motives.

Applied here, it is the missing half of the funding conversation. An investor is not an abstract supply of capital with a view about your company. They are operating inside their own mechanism, with its own clock: a fund with a defined life, ownership thresholds below which a position cannot matter to fund returns, reserve policies, a partnership that has to be carried, and their own investors to whom a story must eventually be told. Their caution about size is usually generated by that machinery rather than by doubt about you.

Which means the ask that works is the one that synchronises with their arithmetic as well as with yours — and that you cannot construct it without knowing what theirs is. It is a reasonable thing to ask about directly, and remarkably few founders do. Fund size, position in the fund's life, target ownership, reserve strategy, what their own timeline for evidence looks like: none of it is secret, most investors will tell you, and all of it changes what a sensible proposal looks like.

The failure mode I have seen most often is not an investor being unreasonable. It is a founder asking for a number without explaining the structural reason behind it, and an investor responding with a smaller number for structural reasons of their own — two rational parties producing an outcome neither of them would have chosen, because neither made their own clock visible to the other.

The diagnostic

The practical value of all this is that it gives you a first question when something is not working — and a better one than the questions usually asked.

When performance disappoints, the instinct is to look for the broken part. Which function is underperforming? Who is not delivering? Occasionally that is the answer. Far more often, in my experience, nothing is broken: two functioning parts have fallen out of phase, and the symptom appears in whichever one happens to be measured most closely. The sales team looks like it is missing. The product team looks slow. Finance looks pessimistic. Each is reporting honestly on its own clock.

So the first question is not what is broken. It is which two of these are running at different speeds. It takes about an hour to answer, and the four numbers you need are ones any company can produce: the real length of the sales cycle measured from first contact rather than from qualification, the period the budget assumes revenue lands in, the months of runway, and the horizon the strategy is written against.

Write them down next to each other. It is remarkable how rarely they are ever placed on the same page, and how obvious the answer is when they are.

Crawling is fine

None of this is an argument for speed. A company will crawl before it walks, and there is nothing wrong with a slow rate — long-cycle businesses are among the most durable there are, and the slowness is inseparable from the switching costs that eventually make them valuable.

What is not survivable is limbs moving independently. A strategy the budget does not fund. A hiring plan the sales cycle cannot carry. A product the market evaluates on a horizon nobody modelled. A raise too small to reach the evidence it was raised to produce. An ownership structure that no longer supports the plan it was meant to finance.

Getting those into time with each other is most of the job of running a company. It is also, I would argue, most of what an investor is underwriting when they back one — though it is rarely what the memo says.